Dr. Lal Path Labs Ltd. — Investor Meet, 30-07-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Dr. Lal PathLabs delivered a strong Q1 FY27. Revenue soared 19.1% YoY to Rs. 798 Cr, marking the highest quarterly growth in four years, with patient volumes up 8.2%. EBITDA grew 28.7% to Rs. 247 Cr (31% margin), while PAT increased 27.2% to Rs. 170 Cr. An interim dividend of Rs. 5/share was declared. Management attributes part of the growth to CGHS price hikes (2-3% benefit) and is expanding rural reach. Strategic acquisitions include 80% in Ghana's Sunshine Healthcare and 30% in innovation-focused Neuome Technologies. Outlook suggests mid-teens revenue growth with sustained margins, prioritizing reinvestment. West India turnaround continues with near double-digit growth.